SCHEMBL7384705

SCHEMBL7384705

O=C(Nc1ccncc1)c1c[nH]c2c1C(=O)CCC2

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 2/20 0.43
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TYK2 P29597 4/20 0.42
JAK2 O60674 4/20 0.42
ROCK2 O75116 2/20 0.42
ROCK1 Q13464 2/20 0.42
HTT P42858 1/20 0.42
NAMPT P43490 1/20 0.41
POLB P06746 1/20 0.41
ITK Q08881 1/20 0.41
JAK1 P23458 2/20 0.40
PRKCI P41743 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KCNMA1 Q12791 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8049526 0.97 KDM4E (0.42) BUB1KDM4EL3MBTL1TYK2JAK2
SCHEMBL4897236 0.87 CFTR (0.49) BUB1KDM4EROCK2ROCK1HTT
SCHEMBL7364883 0.86 LMNA (0.46) KDM4EL3MBTL1ROCK2ROCK1HTT
SCHEMBL7386449 0.85 ALDH1A1 (0.48) BUB1KDM4EHTTNAMPTALDH1A1
SCHEMBL7397423 0.85 NPC1 (0.44) KDM4EROCK2ROCK1HTTPOLB
SCHEMBL7397449 0.85 MAPT (0.47) BUB1KDM4EL3MBTL1ROCK2ROCK1
SCHEMBL7367371 0.85 NTRK3 (0.42) KDM4ETYK2ROCK2ROCK1NAMPT
SCHEMBL7360138 0.85 LMNA (0.43) BUB1KDM4EROCK2ROCK1HTT
SCHEMBL7364057 0.85 MAPT (0.43) ROCK2ROCK1ALDH1A1
SCHEMBL7366047 0.85 ROCK2 (0.42) KDM4EROCK2ROCK1HTTNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6096887-A USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF MEMORY. NEUROGEN CORPORATION (US) 2000-08-01 US claimed
EP-0725775-B1 CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 1998-07-22 EP claimed
WO-1998002433-A1 CERTAIN FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1998-01-22 WO claimed
EP-0725775-A1 CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1996-08-14 EP claimed
WO-1995011885-A1 CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1995-05-04 WO claimed
EP-1064270-A2 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-01-03 EP disclosed
EP-1042299-A1 NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-10-11 EP disclosed
US-6096887-A USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF MEMORY. NEUROGEN CORPORATION (US) 2000-08-01 US disclosed
WO-1999050255-A2 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-07 WO disclosed
WO-1999032454-A1 NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-01 WO disclosed
EP-0725775-B1 CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 1998-07-22 EP disclosed
US-5723462-A SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS NEUROGEN CORPORATION (US) 1998-03-03 US disclosed
EP-0825193-A1 Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands NEUROGEN CORPORATION (US) 1998-02-25 EP disclosed
WO-1998002433-A1 CERTAIN FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1998-01-22 WO disclosed